RAYNHAM, Mass.--(BUSINESS WIRE)--Medrobotics Corp, a surgical products company with core competencies in medical robotics, announced that exemplary, multicenter clinical data on its Flex® Robotic System was presented Sunday afternoon at the American Head & Neck Society International Conference in Seattle. The presenter was Stephan Lang, M.D., Professor of Medicine at the University Hospital Essen, Department of Otolaryngology and Head and Neck Surgery in Essen Germany.
The prospective, single-arm, open-label, post-market, clinical follow-up study enrolled 80 patients between July 2014 and October 2015 at three hospitals in Germany and one in Belgium. The goal was to assess the safety and effectiveness of the Flex® Robotic System when guided by surgeons to treat benign and malignant lesions in the throat. The study concluded “…it is a safe and effective tool in transoral robotic surgery.”
Of the 79 patients on whom Flex® was used, doctors were able to expose, visualize and access the target area in 75 (94%) of the cases. Among patients who were treated or biopsied, 72 of 79 (91%) enjoyed successful completions. Fifty-eight percent of the successful procedures (42 of 72) were performed in areas the surgeons considered difficult to reach, such as the tongue base and vocal chords. There were no device-related adverse events reported.
“My colleagues and I performed the world’s first robotic-assisted cancer procedures with the Medrobotics Flex® Robotic System two years ago,” said Dr. Lang. “The technology has continually improved since then, allowing us better access to challenging surgical sites.
“This unique, flexible system offers a number of surgical advantages over linear robot systems that move in straight lines. The most obvious one is it can navigate the body’s natural curves.”
Medrobotics’ Flex® Robotic System was designed to provide an affordable, easy-to-use robot-assisted surgical platform for hospitals and surgeons seeking to provide minimally-invasive treatment options to the broadest number of patients. Minimally invasive surgery has demonstrated advantages for patients and providers, such as shorter hospital stays and faster recovery times.
About Medrobotics
Medrobotics Corporation (www.Medrobotics.com) is a privately funded medical device company headquartered in Raynham, Massachusetts that manufactures and markets the Flex® Robotic System, the world’s first flexible robotic surgical platform. The Flex® Robotic System offers surgeons the unique ability to navigate complex anatomy minimally invasively and operate in hard-to-reach anatomical locations that might otherwise be inaccessible with straight surgical tools. The Company’s vision is to provide more patients with access to minimally invasive surgery. Medrobotics received FDA clearance for the Flex® Robotic System in July 2015, and the CE mark in March 2014